SIRIO PHARMA CO
SIRIO PHARMA CO., a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a key provider of high-quality pharmaceutical products and services, specialising in contract manufacturing and development. SIRIO PHARMA is renowned for its innovative approach to drug formulation and delivery, offering a diverse range of core products, including solid dosage forms and advanced delivery systems. The company’s commitment to quality and compliance has earned it a strong market position, with notable achievements in regulatory approvals and partnerships with global pharmaceutical firms. With a focus on excellence and customer satisfaction, SIRIO PHARMA continues to drive advancements in the pharmaceutical sector.
DitchCarbon Score
How does SIRIO PHARMA CO's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SIRIO PHARMA CO's score of 16 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SIRIO PHARMA CO's reported carbon emissions
In 2023, SIRIO PHARMA CO reported total carbon emissions of approximately 1,798,600 kg CO2e, comprising 1,300 kg CO2e from Scope 1, 1,798,700 kg CO2e from Scope 2, and 135,600 kg CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 emissions from 1,100 kg CO2e in 2022, while Scope 2 emissions decreased marginally from 1,815,700 kg CO2e. Scope 3 emissions also saw a reduction from 141,300 kg CO2e in the previous year. Despite these figures, SIRIO PHARMA CO has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to monitor its emissions across all scopes, indicating a commitment to transparency in its climate impact reporting. As the pharmaceutical industry increasingly focuses on sustainability, SIRIO PHARMA CO's emissions data reflects the ongoing challenges and opportunities in reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 1,100 | 0,000 |
| Scope 2 | 1,815,700 | 0,000,000 |
| Scope 3 | 141,300 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SIRIO PHARMA CO is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
